Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...atment...
...ew Recommendation from 2022 Guideline Rapid Reco...
...r patients with T1cN1-2 or T2-4N0...
Candida...
...chemotherapy is the treatment of choice for patie...
...or histology, grade, stage and estrogen,...
...systemic therapy should be offered...
...uvant systemic therapy may be offered to redu...
...ts for whom a delay in surgery is prefera...
Measuring Response
...easuring Response
...eiving neoadjuvant therapy should be monitore...
...od- and tissue-based biomarkers should...
...absence of invasive disease in breast and lymph...
Recommended Regimens for Patients with TNBC
...mmended Regimens for Patients with TNBC...
...TNBC who have clinically node positive...
...ents with cT1a or cT1bN0 TNBC should...
...in may be offered as part of a neoadjuvant...
...e is insufficient evidence to recommend routine...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...Neoadjuvant Treatment for Patients with HE...
...ant chemotherapy can be used instead of adjuv...
...ostmenopausal patients with HR+, HER2-ne...
...sal patients with HR+, HER2-negative early-stag...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...nded Neoadjuvant Treatment for Patients wi...
...with node-positive or high-risk node-negati...
...ients with T1a N0 and T1b N0, HER2+ disease...